Picture of Ovoca Bio logo

OVB Ovoca Bio News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

REG - Ovoca Bio PLC - Half-year Report

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250930:nRSd3030Ba&default-theme=true

RNS Number : 3030B  Ovoca Bio PLC  30 September 2025

Ovoca Bio PLC

30 September 2025

 

Ovoca Bio plc

 

("Ovoca" or the "Company")

 

Interim Results for the six months ended 30 June 2025

 

Dublin, Ireland, 30 September 2025 - Ovoca Bio announces its interim financial
statements and report covering the six-months ending 30 June 2025.

 

Please click on the following link to view the full Half Year Report and
extracts are set out at the end of this announcement:

 

Ovoca News - Ovoca Bio (https://ovocabio.com/ovoca-news/)

 

CEO Statement

Today we have published Ovoca's financial statements covering the six-month
period to the end of June 2025, which I encourage all stakeholders to read. On
7 May 2025 the Company entered into a conditional Letter of Intent ("LOI") to
acquire 100% of Tadeen International Limited ("Tadeen"), a UK-registered
company, which indirectly owns 100% of a portfolio of mineral exploration
licenses in Morocco prospective for Copper and Silver (the "Proposed
Acquisition"). The team at Ovoca has been working to complete the Proposed
Acquisition and in due course further announcements will be made as we
finalize the acquisition of Tadeen.

 

As at 30 June 2025, the Company had cash and cash equivalents amounting to
€1,526 million ($ 1,788 million) and we will continue to carefully manage
our financial resources. The costs incurred during the period relate to the
costs of work in relation to the Proposed Acquisition along with corporate
costs.

 

I would like to thank the management team of the Company and the Board of
Directors for their support.

 

End

 

For further information:

 

Ovoca Bio plc

Tim McCutcheon (Chief Executive Officer)

Tel +353 1 661 9819

info@ovocabio.com (mailto:info@ovocabio.com)

 

Beaumont Cornish Limited (Nominated Adviser and Broker)

James Biddle/ Roland Cornish

Tel: +44 (0) 207 628 3396

 

Nominated Adviser Statement

 

Beaumont Cornish Limited ("Beaumont Cornish"), is the Company's Nominated
Adviser and is authorised and regulated in the United Kingdom by the Financial
Conduct Authority. Beaumont Cornish's responsibilities as the Company's
Nominated Adviser, including a responsibility to advise and guide the Company
on its responsibilities under the AIM Rules for Companies and AIM Rules for
Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont
Cornish is not acting for and will not be responsible to any other person for
providing the protections afforded to customers of Beaumont Cornish nor for
advising them in relation to the transaction and arrangements described in the
announcement or any matter referred to in it.

 

Half Year Report

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IR EANNNAAXSEFA

Recent news on Ovoca Bio

See all news